Market Research Report - 228358
Injectable Drug Delivery to 2022
|Published by||Greystone Research Associates|
The past decade has seen a dramatic shift in terms of the types of approved injectable drugs, the diseases they target, and the devices used to deliver them. This shift has fostered change on several levels of the healthcare sector. The injectable drug segment has seen a marked increase in the level of drug/device integration, as prefilled syringes and specialized injection devices proliferate in response to safety and economic challenges posed by recombinant protein drugs, while administration of injectables has moved increasingly from practitioner offices and healthcare facilities to patient homes. This report examines the key therapeutic, product, market and regulatory factors for injectable drugs across ten major disease and therapeutic classes, providing essential insight and forecasts into the implications of this evolving landscape.